← Back to Treatments
🏅 FDA Orphan Designation

HyQvia

Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Manufacturer: Takeda Development Center Americas, Inc.

Indicated for:
Chronic inflammatory demyelinating polyneuropathyOrphan

FDA-Approved Indications (1)

treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults

Indications & Usage

treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.